Articles tagged with Crisprs
A team of scientists at the University of Sydney has repurposed a commonly used blood thinner, heparin, as an inexpensive antidote for cobra venom. The discovery could drastically reduce the impact of snakebites worldwide, particularly in low- and middle-income countries where cobra species account for most snakebite incidents.
Researchers have developed a new method called PUMA that uses CRISPR-Cas12 nucleases to detect RNA biomarkers. This technology overcomes limitations of existing methods by reprogramming tracrRNAs to recognize specific RNA targets, enabling precise detection without requiring a specific recognition sequence.
A team of researchers led by Professor Peter Fineran from the University of Otago discovered a novel regulatory mechanism in a protein used by phages to deploy anti-CRISPR. This finding has significant implications for understanding gene regulation and developing new antimicrobial therapies.
A team of scientists at Gladstone Institutes has developed a new method that enables them to make precise edits in multiple locations within a cell—all at once. They created a tool using molecules called retrons to efficiently modify DNA in bacteria, yeast, and human cells.
A CHARMed collaboration has created a set of molecular tools called CHARMs that can turn off disease-causing genes, including those coding for the prion protein. The tools have shown promise in silencing the prion protein gene and improving or eliminating disease symptoms in animals.
A breakthrough in chrysanthemum breeding uses CRISPR/Cas9 to enhance disease resistance and genetic research. The study establishes a reliable gene-editing system for chrysanthemums, which promises to advance genetic research and improve the breeding of ornamental plants.
Researchers at the University of Sydney have developed SeekRNA, a programmable tool that can precisely target and relocate genetic sequences with high accuracy and flexibility. This breakthrough technology surpasses current limitations of CRISPR, enabling more precise editing and reducing errors.
A new CRISPR-based paper strip test could allow more patients to get the right treatment for the flu, researchers say. The test distinguishes between different influenza types and can be reprogrammed to recognize other viruses.
A new plant gene drive system, CRISPR-Assisted Inheritance (CAIN), has been developed to enhance trait inheritance in plants. The system uses a toxin-antidote mechanism to override Mendelian inheritance, allowing for the spread of beneficial genes at higher rates.
New research reveals that CRISPR/Cas9 gene editing tools have biases against cells from people of African ancestry, leading to false negative results. The study's findings highlight the importance of increasing genetic diversity in large-scale cell line libraries to mitigate this bias.
A new, high-yielding variety of camelina has been engineered with a gene that increases oil production by 21.4%. The modified seeds have lower levels of flavonoid compounds and mucilage, but higher levels of genes involved in oil synthesis.
Researchers used CRISPR to fine-tune sugarcane's leaf angle, capturing more sunlight and increasing biomass production. The study focused on the LIGULELESS1 gene, which plays a major role in determining leaf angle.
Researchers from the University of Illinois have used CRISPR/Cas9 to alter the upstream regulatory DNA of a food crop, increasing gene expression and improving downstream photosynthesis. This approach, which does not require adding foreign DNA, has shown promising results in increasing photosynthetic activity in rice.
Researchers have developed a compact, high-fidelity version of the Cas12a protein, which can be packaged within a non-pathogenic virus for targeted gene editing. The modified protein demonstrates efficient editing activity and has been shown to reduce blood cholesterol levels in mice with high cholesterol.
Scientists at Gladstone Institutes used CRISPR interference to map the layered mechanisms controlling expression of key immune genes. The study provides valuable insights into immune balance, autoimmunity, and cancer immunotherapies, shedding light on genetic variants linked to disease risk and potential treatments.
Researchers from VIB-UGent Center for Plant Systems Biology improved multiplex mutagenesis, reducing the complexity and cost of large-scale genome editing projects. The team optimized CRISPR/Cas9 vector design, achieving a 99% mutation rate with high efficiency.
Researchers have uncovered a unique functionality of CRISPR-Cas Type IV systems, which can silence gene expression at target locations without cutting DNA. This discovery holds promise as a potential biotechnological application to combat antibiotic-resistant superbugs.
Researchers developed Cas9 variants to target non-canonical PAMs in Brassica, expanding genome editing capabilities. The SpRY variant showed high editing efficiency at near-PAM-less sites, enabling precise adenine base editing.
A phase 1/2 trial of CRISPR gene editing has demonstrated safety and efficacy, with measurable improvements in 11 out of 14 participants with a form of inherited blindness. The treatment, EDIT-101, was found to be clinically meaningful for four participants and showed significant improvements in cone-mediated vision.
A pioneering CRISPR gene editing trial has demonstrated significant improvement in vision for 79% of participants with inherited retinal degeneration. The study's findings support further research into the potential of CRISPR-based treatments for inherited blindness.
Researchers at the University of Trento have identified a collection of molecular tools to rewrite DNA, including a compact Cas9 enzyme from the human microbiome. The discovery has potential for gene therapy applications and could speed up the development of therapies for genetic diseases.
A team of scientists has developed a method to edit RNA in human cells using CRISPRs, which could lead to new treatments for genetic diseases. The breakthrough allows for the removal of mutations that cause cystic fibrosis and other diseases.
CRISPR technology holds promise in tackling antimicrobial resistance by re-sensitizing bacteria to first-line antibiotics. However, bacteria have developed anti-CRISPR systems that can repair damage caused by the technology, complicating its effectiveness.
Researchers are developing CRISPR-Cas gene editing technology to modify and attack AMR bacteria, offering new tools to battle the increasing rates of antimicrobial resistance. By targeting specific genes and using phage-based delivery systems, scientists aim to develop safer therapies.
Researchers used medaka fish, CRISPR and new imaging techniques to study embryonic mitosis. They discovered unique spindles assemble in early embryos and found Ran-GTP plays a decisive role in spindle formation, which diminishes later in development. The study paves the way for further exploration of embryonic mitosis.
Researchers used CRISPR-Cas9 to genetically modify kissing bugs, opening a door to controlling Chagas disease. The new method, ReMOT Control, allows efficient and targeted editing of genes in eggs.
Researchers identified a small RNA-binding protein called La that promotes gene editing with high efficiency. The team created a new protein, PE7, which harnesses La's activity to enhance prime editing, leaving unwanted byproducts at low frequencies.
Researchers developed an Integrated Classifier Pipeline (ICP) tool to analyze CRISPR edit outcomes and track unintended 'bystander' edits. The ICP system provides a genetic fingerprint of how material is being inherited, helping scientists untangle complex biological issues.
A new study found that a 'courtship' gene has different effects in two fruit fly species. In one species, giving females the gene resulted in them adopting male behaviors, while in another, it enabled them to produce both male and female songs. The findings suggest that genes can have varying functions across different species.
Researchers successfully demonstrate CRISPR-Cas gene editing technology to eliminate all traces of the HIV virus from infected cells in laboratory settings. The study aims to develop a robust and safe combinatorial regimen to target diverse HIV strains across various cellular contexts.
A new link has been discovered between FBXW7 mutations and EGFR signaling activity in colorectal cancer. The study found that the mutated form of the FBXW7 gene could no longer degrade the EGFR protein, leading to increased signaling activity and a decreased response to anti-EGFR treatment.
Researchers have discovered new genetic mechanisms related to spinocerebellar ataxia type 37, a rare neurological disorder that affects balance and movement. The study employed advanced techniques such as CRISPR/Cas9 gene editing and machine learning to uncover the disease's underlying causes.
A team of researchers used CRISPR-Cas9 gene editing to enhance the nutritional profile and flavor of fungi, creating a new source of plant-based food alternatives. The modified fungi produce heme and ergothioneine, which can improve cardiovascular health benefits.
Tulane University researchers have developed a CRISPR-based platform for diagnosing nontuberculous mycobacteria (NTM) infections, allowing for accurate results in as little as two hours. The blood test can identify over 93% of patients with an NTM infection, enabling rapid treatment plans and reducing the risk of complications.
Researchers create a technique using prime editing to quickly and easily screen cancer genes, revealing new information on p53 mutations. The method allows for the analysis of over 1,000 different mutations in the tumor suppressor gene p53, which are seen in more than half of all cancer patients.
Researchers at CABBI developed a computational pipeline for identifying CRISPR/Cas-facilitated integration sites, which can pinpoint neutral integration sites in two to three minutes. This tool enables researchers to efficiently locate all the needles that align with their specific criteria, transforming the genome editing process.
Researchers have developed a gene editing technique that can repair defective immune cells using CRISPR-Cas9, showing promise in treating rare diseases like Familial Hemophagocytic Lymphohistiocytosis. The therapy involves repairing genetic defects in cytotoxic T cells to normalize the immune response.
A breakthrough gene-editing therapy has been successfully treated over ten patients with hereditary angioedema, reducing symptoms by up to 95% and potentially providing a permanent cure. The therapy targets the KLKB1 gene responsible for producing plasma prekallikrein.
A new CRISPR delivery method enables precise targeting of specific cell subsets in living animals, paving the way for programmable gene therapy. The system uses antibody-targeted 'enveloped delivery vehicles' to selectively edit T-cells and create CAR T-cells.
Researchers have developed CRISPR off-switches to mitigate off-target effects, a major concern in genome editing. The new technology, based on anti-CRISPR proteins, can block CRISPR-Cas3 machine function and prevent unintended edits.
The pAblo·pCasso technology offers unprecedented precision and flexibility in genetic engineering, enabling rapid and precise genetic modifications of bacteria. This breakthrough expands the range of possible genomic editing sites, allowing for temporary modifications and dynamic gene studies.
Researchers from HIRI have developed a new machine learning approach using data integration and AI to improve predictions of CRISPRi efficacy, revealing that gene features matter more than guide RNA itself. The study provides valuable insights for designing effective CRISPRi experiments.
A new study has identified three genes, MANBA, TNFRSF13B, and EEF1A1, as crucial in the regulation of IgG galactosylation, a trait associated with ageing. The research used GWAS to analyze IgG glycosylation phenotypes in a large sample size, increasing the understanding of this complex posttranslational modification.
Recent progress in CRISPR-Cas editing enables tailored probiotic organisms to promote gut health, support immune systems, and enhance metabolism. Genetically modified probiotics have shown potential in preventing or mitigating diseases, such as antibiotic-resistant bacteria and inflammatory bowel disease.
Recent advances in CRISPR-Cas genome engineering enable the creation of novel probiotic strains with potential treatments for various diseases. Genetically modified probiotics show great promise in treating cancers, inflammatory bowel disease, and obesity, while combating antibiotic resistance.
A team of researchers has developed a promising gene-editing strategy for spinal muscular atrophy (SMA), a devastating pediatric neuromuscular disorder. The approach involves using CRISPR base editing to activate the SMN2 gene, which is similar to the mutated SMN1 gene responsible for SMA.
Researchers discovered a novel family of effector proteins called Cami1 that inhibit translation in bacteria attacked by viruses. By cleaving specific mRNAs, Cami1 prevents the production of viral proteins, allowing the bacterium to conserve resources.
Researchers discuss CRISPR's limitations in generating accurate cancer models, including variable mutations and indels. Despite these challenges, the technology holds promise for cancer research due to its potential for natural selection and Darwinian evolution.
Researchers at the University of Copenhagen discovered that phages use small RNAs to disarm bacterial CRISPR-Cas immune systems, making them vulnerable to infection. This finding has significant implications for phage therapy and could lead to more specific and controlled CRISPR-Cas treatments.
Scientists at Florida State University produced the first high-resolution images showing magnesium ions playing a crucial role in CRISPR-Cas9's DNA-cutting process. The discovery sheds light on how magnesium coordinates double-stranded breaks, providing new insights into the enzyme's functioning.
A novel replacement strategy using CRISPR-Cas9 and recombinant DNA donor vectors is proposed to precisely replace disease-causing genes in SCID patients. This approach preserves regulatory elements and intronic sequences, reducing the risk of unregulated gene expression.
Researchers used gut organoids to study gut cell differentiation, identifying ZNF800 as a key regulator of enteroendocrine cells. The discovery could have implications for understanding gastrointestinal diseases and endocrine disorders.
Researchers have developed a novel approach, REVeRT, to efficiently transport large genes using dual AAV vectors at the transcript level. This new method offers increased efficiency, fewer side effects, and greater flexibility compared to existing strategies.
Researchers have identified a new mechanism by which phages evade CRISPR-Cas immune systems in bacteria, revealing a potential approach to make gene editing safer and more efficient. This discovery could lead to the development of bespoke anti-CRISPRs to neutralize CRISPR-Cas systems and provide an alternative to antibiotics.
Researchers have developed a new method to study muscle diseases, reducing the number of experimental animals needed. This method enables the simultaneous investigation of several genes or entire signaling pathways in muscle fibers quickly and efficiently.
Researchers created a new CRISPR-based gene therapy tool using locally sourced, human-derived proteins that can activate silent or insufficiently expressed genes. The DREAM tool mimics the natural ability of human cells to turn on specific genes in response to mechanical cues.
Researchers at Kyoto University discovered that liverwort Marchantia polymorpha uses gibberellin precursors to produce a signaling molecule aiding survival under shaded conditions. This metabolic pathway inheritance provides insight into the evolution of plant hormone responses.
A new CRISPR-based gene-editing tool, AsCas12f, has been developed with enhanced editing ability and compact size. The engineered enzyme has already shown success in animal trials and holds promise for improved treatments of genetic disorders.
Rice University scientists developed a tiny CRISPR-Cas13 system to shred viruses by targeting RNA. The system's unique mechanism and three-dimensional structure were mapped using cryo-electron microscopy, allowing researchers to engineer it for improved precision and specificity.
Researchers at Rice University have developed a non-invasive gene delivery technique using ultrasound to efficiently deliver clinically used gene therapy vectors throughout the brain. The study, published in Gene Therapy, shows that opening more sites within targeted regions improves gene delivery efficiency.